Gadopentetate dimeglumine (SH-L-451A)
(Synonyms: 钆喷酸葡胺; SH-L-451A; Gadopentetic acid dimeglumine salt) 目录号 : GC33456
Gadopentetate Dimeglumine (Gadopentetic acid dimeglumine, Gd-DTPA, Meglumine gadopentetate), a complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid, is an extracellular intravenous contrast agent used in magnetic resonance imaging.
Cas No.:86050-77-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Rats: Twenty-eight rats are anesthetized and midline laparotomy is performed. Animals are divided into four groups: control, ligation of a single mesenteric arcade, ligation of six consecutive arcades, and ligation of the anterior mesenteric artery (analogous to the superior mesenteric artery in humans). A 1.0-mL enteric bolus of gadopentetate dimeglumine diluted with sterile water (1:1) is given via gavage. Magnetic resonance imaging is performed 2 hr after laparotomy and reviewed for the presence of intraperitoneal gadopentetate dimeglumine by two experienced observers. Animals are sacrificed 24 hr after surgery for pathologic examination[3]. Mice: MR lymphography are performed after the subcutaneous injection of gadopentetate dimeglumine (Gd-DTPA) or gadoxetate disodium (Gd-EOB-DTPA) (0.1, 0.5, or 2.0 mmol per mouse) into the right footpad in six healthy mice, and the time courses of contrast enhancement are assessed. Additionally, the lymphatic pathways from two distinct sites are assessed in tandem by interstitial MR lymphography studies[2]. |
References: [1]. Gilbert FJ, et al. Comparison of gadobenate dimeglumine-enhanced breast MRI and gadopentetate dimeglumine-enhanced breast MRI with mammography and ultrasound for the detection of breast cancer. J Magn Reson Imaging. 2014 May;39(5):1272-86. | |
Gadopentetate Dimeglumine (Gadopentetic acid dimeglumine, Gd-DTPA, Meglumine gadopentetate), a complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid, is an extracellular intravenous contrast agent used in magnetic resonance imaging.
| Cas No. | 86050-77-3 | SDF | |
| 别名 | 钆喷酸葡胺; SH-L-451A; Gadopentetic acid dimeglumine salt | ||
| Canonical SMILES | O=C1[O-][Gd+3]([N]2(C3)CC4=O)([N]5(C6)CC7=O)([O-]C6=O)([O-]7)([O-]C3=O)([O-]4)[N](CC5)(CC2)C1.O[C@H]([C@@H](O)CNC)[C@H](O)[C@H](O)CO.O[C@H]([C@@H](O)CNC)[C@H](O)[C@H](O)CO.[2H+] | ||
| 分子式 | C28H54GdN5O20 | 分子量 | 938 |
| 溶解度 | DMSO : 5 mg/mL (5.33 mM) | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.0661 mL | 5.3305 mL | 10.661 mL |
| 5 mM | 0.2132 mL | 1.0661 mL | 2.1322 mL |
| 10 mM | 0.1066 mL | 0.533 mL | 1.0661 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Gadopentetate dimeglumine-enhanced MR cholangiopancreatography in infants with cholestasis
Pediatr Radiol 2011 Apr;41(4):488-94.PMID:21127853DOI:10.1007/s00247-010-1911-4.
Background: Biliary atresia (BA) is a progressive, obliterative cholangiopathy that occurs in neonates with hepatic portoenterostomy the treatment of choice, but early surgery is important for optimum outcomes. MRI, including MR cholangiopancreatography (MRCP) may be a diagnostically useful alternative to US, but the heavily T2-weighted sequences used include not only bile duct signals, but also other heterogeneously high signal intensities from surrounding structures. Objective: To evaluate the effects of gadolinium when used to decrease background signal intensity on T2-weighted MR cholangiopancreatography (MRCP) in infants and to evaluate the qualitative improvement of the depiction of the common bile duct (CBD) for evaluating neonatal cholestasis. Materials and methods: Our Institutional Review Board approved this prospective study. MRCP was performed with Gadopentetate dimeglumine injection using a 1.5-T scanner. Pre- and postcontrast MRCP images were compared. Forty-nine infants (male:female = 21:28; age 0-12 months, mean 2.3) were included. The final diagnoses were biliary atresia (BA) in 28 cases and non-BA in 21. Quantitative analysis was conducted using region-of-interest measurements of mean signal intensities of the liver, pancreatic head and gallbladder (if defined). Qualitative analysis was performed by four radiologists who subjectively scored image confidence in the presence of CBD on a 4-point scale (0 for definitely absent, 1 for probably absent, 2 for probably present, and 3 for definitely present). Results: The signal-to-noise ratios were significantly decreased in the liver and pancreatic head after contrast medium enhancement (mean 5.7→4.0 in liver and mean 44.9→12.7 in the pancreatic head; P < 0.0001), and this finding was constant in both the BA and the non-BA group. The mean confidence score in the presence of CBD decreased in the BA group (0.9→0.5; P < 0.0001), but did not change significantly in the non-BA group (2.0→2.1; P = 0.459) after contrast medium enhancement. Both intra- and interobserver agreement was higher after contrast medium enhancement (P = 0.046). Conclusion: Gadopentetate dimeglumine-enhanced MRCP increased the diagnostic confidence of absence of the CBD in cholestatic infants with increased intra- and interobserver agreement.
Contrast-enhanced three-dimensional MR portography
Radiographics 1999 Jul-Aug;19(4):973-87.PMID:10464804DOI:10.1148/radiographics.19.4.g99jl02973.
Three-dimensional (3D) magnetic resonance (MR) portography with contrast material enhancement is a fast means of evaluating the portal venous system that has some advantages over currently used modalities, such as digital subtraction angiography, helical computed tomography, ultrasonography, and nonenhanced MR angiography with time-of-flight and phase-contrast techniques. With contrast-enhanced 3D MR portography, a first-pass study of the mesenteric vasculature is performed after rapid bolus injection of Gadopentetate dimeglumine; a 3D fast field echo sequence is used, which can demonstrate the intrahepatic and extrahepatic portal venous system clearly. Repeated sequences after administration of Gadopentetate dimeglumine allow separate demonstration of the splanchnic arteries and portomesenteric veins. The images are reconstructed by means of maximum-intensity projection postprocessing, and a subtraction technique can be used to eliminate arterial enhancement and demonstrate portosystemic shunts. The coronal source images simultaneously demonstrate parenchymal lesions of the liver, pancreas, biliary tract, and spleen. This technique is clinically indicated in portosystemic shunt, portal vein thrombosis, hepatocellular carcinoma, pancreatobiliary tumor, hepatic vein obstruction, differentiation of splanchnic arterial from portal venous disease, and gastrointestinal hemorrhage. Its limitations include allergic reactions to contrast media, inappropriate positioning of the 3D acquisition slab, respiratory motion artifacts, and pseudodissection.
Gadopentetate dimeglumine-enhanced MR imaging of the musculoskeletal system
AJR Am J Roentgenol 1991 Mar;156(3):457-66.PMID:1899738DOI:10.2214/ajr.156.3.1899738.
Contrast-enhanced MR imaging with Gadopentetate dimeglumine has been used in the evaluation of musculoskeletal disorders only in recent years, and for the most part it is still under investigation. Review of the literature identified potential uses for this technique: (1) in the spine, for differentiation between scar tissue and recurrent disk herniation and for evaluation of epidural tumors; (2) in musculoskeletal tumors, for differentiation between tumor necrosis and peritumoral edema and for characterization and evaluation of tumors before and after treatment; (3) in the joints for delineation of cartilage and tendon tears, with intraarticular injection, and for differentiation between pannus and joint effusion, with IV injection; and (4) for delineation of infectious processes. Further studies are needed to confirm most of these potential indications. It is unlikely that gadopentetate dimeglumine-enhanced MR imaging will become a routine part of musculoskeletal MR imaging, and its use will be reserved for specific circumstances.
Effect of abrupt substitution of gadobenate dimeglumine for Gadopentetate dimeglumine on rate of allergic-like reactions
Radiology 2013 Mar;266(3):773-82.PMID:23238152DOI:10.1148/radiol.12120253.
Purpose: To evaluate the effect of abruptly substituting gadobenate dimeglumine for Gadopentetate dimeglumine on allergic-like reactions. Materials and methods: The institutional review board approved and waived patient consent for this HIPAA-compliant retrospective study. Allergic-like reactions related to gadolinium-based contrast media were assessed 2 years before and 3.5 years after gadobenate dimeglumine was substituted for Gadopentetate dimeglumine. Reaction rates and severity were compared by using χ(2) tests, Fisher exact tests, odds ratios (ORs), and confidence intervals (CIs). Results: Allergic-like reactions (137 mild, 19 moderate, and six severe) occurred in 162 (0.15%) of 105 607 injections of gadolinium-based contrast media (Gadopentetate dimeglumine, 31 540; gadobenate dimeglumine, 66 152; other, 7915). Gadobenate dimeglumine was associated with significantly more overall (0.19% [123 of 66 152] vs 0.08% [24 of 31 540]; OR, 2.4; 95% CI: 1.6, 3.8; P < .0001) and mild (0.16% [107 of 66 152] vs 0.06% [18 of 31 540]; OR, 2.8; 95% CI: 1.7, 4.7; P < .0001) allergic-like reactions than was Gadopentetate dimeglumine. The reaction rate for gadobenate dimeglumine peaked (maximum per quarter, 0.38% [16 of 4262]; minimum per quarter, 0.07% [three of 4237]) in the 2nd year after it replaced Gadopentetate dimeglumine (maximum per quarter, 0.10% [four of 4122]; minimum per quarter, 0.05% [two of 4222]) and then declined in the 3rd year. The final gadobenate dimeglumine reaction rate (last 3 quarters, 0.12% [17 of 14 387]) did not significantly differ from the original baseline reaction rate with Gadopentetate dimeglumine. Conclusion: After gadobenate dimeglumine was substituted for Gadopentetate dimeglumine, a significant transient increase occurred in the frequency of reported allergic-like reactions that demonstrated a temporal pattern suggestive of the Weber effect (a transient increase in adverse event reporting that tends to peak in the 2nd year after a new agent or indication is introduced). © RSNA, 2012.
Molecular imaging of cerebrovascular lesions
Transl Stroke Res 2014 Apr;5(2):260-8.PMID:24323714DOI:10.1007/s12975-013-0291-0.
Inflammation is a key component in the pathogenesis of cerebrovascular lesions. Two agents have emerged as promising possibilities for imaging cerebrovascular lesions. These agents are ferumoxytol and myeloperoxidase (MPO)-specific paramagnetic magnetic resonance (MR) contrast agent. Ferumoxytol is an iron oxide nanoparticle coated by a carbohydrate shell that is used in MRI studies as an inflammatory marker as it is cleared by macrophages. Ferumoxytol-enhanced MRI allows noninvasive assessment of the inflammatory status of cerebral aneurysms and arteriovenous malformations and, possibly, may differentiate "unstable" lesions that require early intervention from "stable" lesions that can be safely observed. Several pilot studies have also suggested that MPO-specific paramagnetic MR contrast agent, di-5-hydroxytryptamide of Gadopentetate dimeglumine, may allow imaging of inflammation in the wall of saccular aneurysms in animal models. However, studies in human subjects have yet to be performed. In this paper, we review current data regarding ferumoxytol-enhanced MRI and MPO-specific paramagnetic MR contrast agent and discuss current and future applications.